Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 73 Publications

13 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).



    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).



    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Three MET amplified (Hs746t, SNU-5 and MKN45) and two non-amplified cell lines (MKN74 and NUGC-4) were incubated with or without 100nM crizotinib 24 hours, and total protein was extracted using RIPA lysis buffer. Total lysates were then analyzed by immunoblotting using anti-phospho-MET, anti-total-MET, and β-actin antibodies.

    Oncotarget, 2017, 8(31):51675-51687. Crizotinib (PF-02341066) purchased from Selleck.

    Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.



    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 M2fJU2N6fG:2b4jpZ{BCe3OjeR?= MnPrOFghcA>? M{HOT2ROW09? MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIF[xNVc1VCCvdYThcpQh[2:neIDy[ZN{cW6pIFXNUFQhf2m2aDDJR|UxKG:oIECuOlIh|ryP MV[yNVU4OjV6OR?=
Kelly MnPxR5l1d3SxeHnjJGF{e2G7 NHPUU2FFVVOR NXvNSGVES3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU2WubImgZ4VtdHNiZYjwdoV{e2mwZzDBUGshTjFzN{TMJI12fGGwdDD3bZRpKEmFNUCgc4YhOC52MjFOwG0> MX6yNVU4OjV6OR?=
SH-SY5Y Mo\6R5l1d3SxeHnjJGF{e2G7 NYHRZ4toTE2VTx?= MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPTNizszN NFzOTpozOTV5MkW4PS=>
BAF3 M37acmN6fG:2b4jpZ{BCe3OjeR?= M4nMWFQ5KGh? NXXxbIxuTE2VTx?= NU\sUZdMS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIGTlcE1CVEtid3n0bEBKSzVyIH;mJFAvOTlizszN NYrNWpA6OjF3N{K1PFk>
3T3 MlvXSpVv[3Srb36gRZN{[Xl? MoH6NUBp NH\nVGZFVVOR MVLJcohq[mm2aX;uJI9nKFKRTjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yODFOwG0> Mn7INlE5OTJ2MUS=
3T3-E MX\GeY5kfGmxbjDBd5NigQ>? Ml;SNUBp MnXmSG1UVw>? NEeyUpVKdmirYnn0bY9vKG:oIGTJSVIh[XO|ZYPz[YQh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNES4JO69VQ>? M1[yOFIyQDF{NEG0
A549 NInHbnJMcW6jc3WgRZN{[Xl? Mn\BNUBp NWjBR2syTE2VTx?= M4fjdWlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiYz3NSXQhc2mwYYPlJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGhITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODB6IN88US=> Ml3UNlE5OTJ2MUS=
BAF3-BCL NVX0TJZ7TnWwY4Tpc44hSXO|YYm= M2fYV|EhcA>? MX3EUXNQ NIP6[5RKdmirYnn0bY9vKG:oIFHCUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMT6xOVkh|ryP MlrVNlE5OTJ2MUS=
HEK293 NYK2cItZTnWwY4Tpc44hSXO|YYm= MYCxJIg> M4\BdmROW09? Mlm3TY5pcWKrdHnvckBw\iCDWFygZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMkm0JO69VQ>? NUjaWVhROjF6MUK0NVQ>
HEK293 NYLQOpExTnWwY4Tpc44hSXO|YYm= NGXxSVUyKGh? NX;R[pRSTE2VTx?= MofYTY5pcWKrdHnvckBw\iCLUjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi56OEeg{txO Ml24NlE5OTJ2MUS=
Jurkat MnfLSpVv[3Srb36gRZN{[Xl? M3XOSVEhcA>? NWDHNJl[TE2VTx?= M4XNU2lvcGmkaYTpc44hd2ZiTFPLJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iB{Lke0NUDPxE1? MYKyNVgyOjRzNB?=
KARPAS299 MULLbY5ie2ViQYPzZZk> NYC0[2kyOSCq M3jHXmROW09? MWfJcohq[mm2aX;uJI9nKEGOSzDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMjFOwG0> MUiyNVgyOjRzNB?=
PAE M4Toc2Z2dmO2aX;uJGF{e2G7 NF\pdHcyKGh? M2CxR2ROW09? NX\hOZZWUW6qaXLpeIlwdiCxZjDUVmtDKGG|c3Xzd4VlKGG|IHfyc5d1cCCoYXP0c5IucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlM6QSEQvF2= MoO3NlE5OTJ2MUS=
BAF3 MWrGeY5kfGmxbjDBd5NigQ>? NVv3S2lxOi1|IHS= M4jqcmROW09? MoLkTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiaX7zeYxqdiC{ZXPldJRweiCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEvPjR|IN88US=> NWXoeIZ[OjN5NEKyOVI>
KARPAS299 Mmr5R5l1d3SxeHnjJGF{e2G7 M4PmU|IuOyCm NGj0cXlFVVOR NX\nWYtNUUN3ME2wMlA3PDJizszN MUWyN|c1OjJ3Mh?=
EBC1 NHPLXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W0b|czKGh? M37NTGROW09? M2f3PWlEPTB;MD6wNlMh|ryP MWKyN|k6OzN{OB?=
HCT116 NIWx[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILzSG44OiCq MUXEUXNQ NI\SfYtKSzVyPUG0MlgzKM7:TR?= NX70fXplOjN7OUOzNlg>
MCF7 M2f3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXu3NkBp MknGSG1UVw>? MlnoTWM2OD17LkW4JO69VQ>? NGXyepYzOzl7M{OyPC=>
MDA-MB-231 NEnpdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrGOoNjPzJiaB?= NXvMeJRrTE2VTx?= MlfpTWM2OD1zMD64JO69VQ>? NIe5[3YzOzl7M{OyPC=>
MKN45 M33aVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUi3NkBp NGPFVXdFVVOR M3nRcGlEPTB;MD6wNVMh|ryP M13TfVI{QTl|M{K4
NCI-H441 NXP2PI15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPBO|IhcA>? M1PYcGROW09? MlzyTWM2OD1zNz6yOUDPxE1? M3;QNFI{QTl|M{K4
NCI-H661 NWHVO4c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTqN5VYPzJiaB?= MkT2SG1UVw>? M3TycWlEPTB;MUGuOFch|ryP MnzwNlM6QTN|Mki=
SK-MEL-28 NHnOeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHsTG84OiCq MVvEUXNQ NUfVXI92UUN3ME2xNE46PyEQvF2= NYfySmNuOjN7OUOzNlg>
SKOV3 MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjTO|IhcA>? NGXxfodFVVOR NYDjToR6UUN3ME2xNk45PSEQvF2= MWeyN|k6OzN{OB?=
SNU5 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXO3NkBp MlX1SG1UVw>? MUHJR|UxRTBwMEG2JO69VQ>? Mly3NlM6QTN|Mki=
NCI-H2228 M1T4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHjVnE4OiCq MUPEUXNQ NV32T|BoUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUG4JO69VQ>? MXyyOFQ{OjlyOR?=
NCI-H3122 NIfzVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTiUZM4OiCq M2fnXGROW09? M4HUPGlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjFyODFOwG0> MmHMNlQ1OzJ7MEm=
NCI-H3122 NG\RcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\QWnIzPzJiaB?= NUjiSnVHTE2VTx?= NF:yPYdKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiaHHyZo9zcW6pIFHMT{BIOTJ4OVGgcZV1[W62IIfpeIghUUN3MDDv[kAxNjZ{MzFOwG0> NF2zS4szPDR|MkmwPS=>
NCI-H3122 NEK5bZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWG3NkBp MoDoSG1UVw>? MV7Jcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDMNVE6Pk1ibYX0ZY51KHerdHigTWM2OCCxZjCwMlg{QCEQvF2= NHrDfoszPDR|MkmwPS=>
NIH-3T3 Mkn5T4lv[XOnIFHzd4F6 MX2xJIg> NYLTUGdtTE2VTx?= NHW4dXBKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJHMyOjB4WTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLk[yOkDPxE1? NXLCOFdHOjR2M{K5NFk>
NIH-3T3 NEfFeoZMcW6jc3WgRZN{[Xl? NWfsfFlnOSCq NGfjOXdFVVOR MWHJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVk3VSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjh2MzFOwG0> MnToNlQ1OzJ7MEm=
NIH-3T3 NG\TRXhMcW6jc3WgRZN{[Xl? NIT0cm4yKGh? M3T5UWROW09? Ml\6TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE2OlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5yMk[g{txO M3HFV|I1PDN{OUC5
BAF3 NILOXY1HfW6ldHnvckBCe3OjeR?= MkDGO|IhcA>? MlLqSG1UVw>? NVnGb2c{UW6qaXLpeIlwdiCxZjDOVG0wSUyNIITyZY5{\mWldHXkJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEWxJO69VQ>? M2e5U|I1PDZ6NkOy
BAF3 NEPK[XJEgXSxdH;4bYMhSXO|YYm= NFjlbFI4OiCq M3;wVmROW09? Mm\wTWM2OD1yLkm4JO69VQ>? NEXudm0zPDR4OE[zNi=>
NIH-3T3 MkP4T4lv[XOnIFHzd4F6 NF3WVXUyKGh? MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIF[xNVc1VCCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjF4NTFOwG0> MW[yOFgyQTFzNh?=
NIH-3T3 NGq3S3lMcW6jc3WgRZN{[Xl? NI[zeWcyKGh? M4HoRWlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugR|EyPT[\IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNEe4JO69VQ>? M3[xUVI1QDF7MUG2
NIH-3T3 NVnnfVR4U2mwYYPlJGF{e2G7 NVXzPIpkOSCq NH3zepZKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjB{UjDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iBzLkG0PEDPxE1? M{jsdlI1QDF7MUG2
NIH-3T3 MlnNT4lv[XOnIFHzd4F6 NGnwfZYyKGh? NXHJVHd4UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{AyOTVzVHnud{BufXSjboSg[ZhxemW|c3XkJIF{e2W|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKHerdHigTWM2OCCxZjCzMlA{QSEQvF2= NUXtOpJ5OjR6MUmxNVY>
KARPAS299 MX;LbY5ie2ViQYPzZZk> MkjiPVAhdWmw MWnEUXNQ M4\McWlvcGmkaYTpc44hd2ZiTmDNMYZ2e2WmIFHMT{BxcG:|cHjvdplt[XSrb36g[ZhxemW|c3XkJJdqfGhiSVO1NEBw\iByLkGxJO69VQ>? NX63fGcxOjR7MEC3OVA>
MKN 45 NFOyVpNMcW6jc3WgRZN{[Xl? MlLJNUBp MUnEUXNQ M{T1dWlvcGmkaYTpc44hd2ZiYz3N[ZQheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>? NUnMTXg3OjR7MEC3OVA>
A549 MmHBR5l1d3SxeHnjJGF{e2G7 MYG0PEBp NXrGVpQ2TE2VTx?= MXzJR|UxKG:oIESuNFg1KM7:TR?= MViyOFkxODh|MB?=
NCI-H1993 MU\BdI91d3OrczDBd5NigQ>? NIfTWmYyKM7:TR?= M1f2b|I1KGh? NX71cJlJTE2VTx?= M1j5PYRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= M{n3dFI1QTByOEOw
NIH-3T3 NH[xS4JEgXSxdH;4bYMhSXO|YYm= MlXPOFghcA>? M1e3Z2ROW09? NW\EfoxmUUN3MDDv[kAxNjN4NDFOwG0> MW[yOFkxODh|MB?=
EBC1 NXjFbYRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3rdpc3PzJiaB?= MV\EUXNQ Ml\NTWM2OCCxZjCwMlAxPjlizszN M1\3SVI1QTByOEOx
NB1 MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTlzLkm4JI5O NYj1VGRYW0GQR1XS
SR NXfZb|hNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn0TWM2OD1zMk[uN|Ehdk1? NILPSZBUSU6JRWK=
SF539 NELXe3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3MVXl{UUN3ME2yNFQvOjRibl2= NUDFTHAyW0GQR1XS
SU-DHL-1 M37Zemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTVTWM2OD1|M{[uPFIhdk1? MoO1V2FPT0WU
SCC-3 NFPB[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rG[mlEPTB;M{W2Mlc3KG6P NE\JTmdUSU6JRWK=
DEL M{jyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnXTWM2OD1|NkmuPUBvVQ>? NXnpVWhlW0GQR1XS
CTV-1 NXvZcVZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M176[2lEPTB;NUm2MlQ5KG6P NWSweYdoW0GQR1XS
EM-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3qxOmlEPTB;NkCxMlM1KG6P NIDQe3BUSU6JRWK=
MHH-CALL-2 M3jXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;XPYcyUUN3ME22PFIvPTdibl2= NVzHepZPW0GQR1XS
KINGS-1 M13GOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjwPXlKSzVyPUe0PU44PSCwTR?= MVfTRW5ITVJ?
MEG-01 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v0e2lEPTB;OEW3MlY3KG6P MkjPV2FPT0WU
KARPAS-299 M3LWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLxTWM2OD1zLkSwPFYyKM7:TR?= MkS5V2FPT0WU
K-562 MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFwN{KyOlkh|ryP MkjCV2FPT0WU
CMK M3y4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vITGlEPTB;MT65OlE2QSEQvF2= M{\uWXNCVkeHUh?=
ST486 MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DyXGlEPTB;Mj60N|A4OyEQvF2= Ml;pV2FPT0WU
CI-1 NXn1d|gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\h[2lEPTB;Mj60PVY2QSEQvF2= NWL0Tm9oW0GQR1XS
KS-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;OTWM2OD1|LkKxNlI2KM7:TR?= MXrTRW5ITVJ?
Becker MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvnNnVWUUN3ME20MlI{QTNizszN NEDHdGhUSU6JRWK=
GDM-1 M1fpe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrOT3RKSzVyPUSuNlQ3OTdizszN NULxR3B[W0GQR1XS
BC-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOxc4xKSzVyPUSuOFkzPzdizszN M{XNTXNCVkeHUh?=
NB14 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn3NZg6UUN3ME20Mlg{PTJ2IN88US=> NUDKZ4VOW0GQR1XS
NOS-1 NH\n[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfwR|hKSzVyPUWuN|M5PzRizszN MYrTRW5ITVJ?
MZ1-PC NHT2dJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXu5U2g{UUN3ME21MlgzOTVzIN88US=> MYPTRW5ITVJ?
A498 Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3KzeGlEPTB;Nj6wPFQ4OyEQvF2= MY\TRW5ITVJ?
EW-16 NEnVNZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4riTWlEPTB;Nj6zO|c4OyEQvF2= MmC1V2FPT0WU
NALM-6 M4HLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nLV2lEPTB;Nj62PFM5PyEQvF2= MYPTRW5ITVJ?
EB-3 NVLXTpcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTTbphEUUN3ME23MlA4OjN|IN88US=> M1rWPXNCVkeHUh?=
697 Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLzTWM2OD17LkK0N|I6KM7:TR?= M121UHNCVkeHUh?=
Ramos-2G6-4C10 NFfoNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfxWYJVUUN3ME25MlU6QDR{IN88US=> NWnOdYxSW0GQR1XS
KNS-81-FD MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPlTWM2OD17Lk[5OlU{KM7:TR?= MW\TRW5ITVJ?
HUTU-80 M1TGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHGe3lWUUN3ME25Mlc1PjR{IN88US=> MYjTRW5ITVJ?
LS-411N M1XXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PRPGlEPTB;MUCuNFU3PyEQvF2= Mni3V2FPT0WU
RPMI-8402 NInxS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFyLkGxOkDPxE1? MYPTRW5ITVJ?
KU812 NXGzXHU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjrcndKSzVyPUGwMlI6QTFizszN M4jrVHNCVkeHUh?=
NB69 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf2UmdKSzVyPUGwMlUxPDNizszN M2LibXNCVkeHUh?=
MFH-ino M1K2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\qWWlKSzVyPUGwMlg{ODNizszN MYHTRW5ITVJ?
NCI-H720 NHjhUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm1SXA{UUN3ME2xNk4yPzB3IN88US=> NGru[WZUSU6JRWK=
HCC1187 M2DkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF{LkKwOFEh|ryP M1vyVnNCVkeHUh?=
IST-SL2 NXfvb|N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7pRopKSzVyPUGyMlQ5PzJizszN MVXTRW5ITVJ?
KE-37 MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T6[WlEPTB;MUKuO|k3PiEQvF2= Mn;YV2FPT0WU
HCC1599 Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn25TWM2OD1zMj65NFY6KM7:TR?= NWDlbIVQW0GQR1XS
A4-Fuk MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHKTWM2OD1zMj65OVg3KM7:TR?= Mmf3V2FPT0WU
NKM-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH1fmhxUUN3ME2xN{4zQTJ3IN88US=> M4H0XHNCVkeHUh?=
BE-13 NWHqdFVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;6TWM2OD1zMz63PVg6KM7:TR?= MYfTRW5ITVJ?
MV-4-11 NETTSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPBTWM2OD1zND6wN|I1KM7:TR?= MkDtV2FPT0WU
KARPAS-422 NVfTOYFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[0TWM2OD1zND61NVI3KM7:TR?= M3vjSnNCVkeHUh?=
RPMI-8226 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16zSGlEPTB;MUSuPFkyPSEQvF2= MW\TRW5ITVJ?
KARPAS-45 MnS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjxdGNKSzVyPUG1Mlc4OTZizszN MWrTRW5ITVJ?
SK-PN-DW MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHrTWM2OD1zNT64OlMyKM7:TR?= NYLqUJc4W0GQR1XS
LC-2 NUDU[mloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL5U2dKSzVyPUG2MlE2ODZizszN MojkV2FPT0WU
NCI-H1648 MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLyTWM2OD1zNj6yOVQh|ryP NYW5PVVoW0GQR1XS
RL95-2 MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;DNXpJUUN3ME2xOk4{QTd6IN88US=> NFvze2ZUSU6JRWK=
KNS-42 M1TMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXHRlVYUUN3ME2xOk44Ojd2IN88US=> NHfic49USU6JRWK=
RPMI-6666 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjEOGcxUUN3ME2xOk46OjFzIN88US=> M3vuW3NCVkeHUh?=
VA-ES-BJ MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHWTWM2OD1zNz63OFUyKM7:TR?= M{PNV3NCVkeHUh?=
MONO-MAC-6 M3:zXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvqXYdKSzVyPUG3Mlk{OTJizszN NV\POGlnW0GQR1XS
LAN-6 NGjQPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjsOY01UUN3ME2xPE44PTV5IN88US=> M4O2OHNCVkeHUh?=
A388 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC2TWM2OD1zOT6zNFU6KM7:TR?= MV;TRW5ITVJ?
SK-NEP-1 MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJyLkKxN|Ih|ryP Mk\pV2FPT0WU
TE-10 NUfJR2xuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJyLkWyNlEh|ryP M3PtOnNCVkeHUh?=
MC116 MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XG[WlEPTB;MkGuO|IzOSEQvF2= M1viZXNCVkeHUh?=
NOMO-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\mTWM2OD1{Mj62OVY1KM7:TR?= MV3TRW5ITVJ?
CTB-1 MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\lcGlEPTB;MkKuPFY4OSEQvF2= MYjTRW5ITVJ?
MRK-nu-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XBXmlEPTB;MkKuPVA4PCEQvF2= NHjBS2pUSU6JRWK=
GR-ST MmD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX4T5dWUUN3ME2yN{44PiEQvF2= MnvyV2FPT0WU
NCI-H1963 NUfzTHc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS5PZJpUUN3ME2yOE4xPzh{IN88US=> MUjTRW5ITVJ?
CGTH-W-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrzXo1TUUN3ME2yOU4xPzJ|IN88US=> MUfTRW5ITVJ?
LP-1 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnz5TWM2OD1{NT62OVUyKM7:TR?= NW\yZndTW0GQR1XS
NCI-H748 NGi2[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[4d|FsUUN3ME2yOk42OTN5IN88US=> MmiyV2FPT0WU
PF-382 NFnOTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJ5LkKyNlMh|ryP MojZV2FPT0WU
ATN-1 NWDIWlJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOyTWM2OD1{Nz6zO|MzKM7:TR?= M4PCdnNCVkeHUh?=
L-540 NXr5OGpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJ5Lk[0OVkh|ryP MVvTRW5ITVJ?
LXF-289 Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\ES4VHUUN3ME2yO{44PTF7IN88US=> MULTRW5ITVJ?
LS-513 NUT0ZZg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Pjc2lEPTB;MkiuNVgxPyEQvF2= M3rXSnNCVkeHUh?=
NCI-H1581 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXqU4RYUUN3ME2zNE4{QTd4IN88US=> M2rqbHNCVkeHUh?=
ES6 NFj3TnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGix[IFKSzVyPUOwMlY5QTlizszN Mnf2V2FPT0WU
MPP-89 MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK3TWM2OD1|ND6xO|U3KM7:TR?= MUPTRW5ITVJ?
NB5 Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37xRWlEPTB;M{SuPFU{PSEQvF2= NXHFbo1FW0GQR1XS
TE-15 NF7yd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TrSGlEPTB;M{WuNlI{QCEQvF2= NIDjVVBUSU6JRWK=
LC4-1 NITFRlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlf0TWM2OD1|NT6zPFQ4KM7:TR?= NXP3[mg2W0GQR1XS
NTERA-S-cl-D1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTYe3lKSzVyPUO4Mlc{PDdizszN MmTYV2FPT0WU
TGW M2GyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTRzLkC1OlMh|ryP MVnTRW5ITVJ?
ONS-76 MnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS0TWM2OD12Mj60PFg{KM7:TR?= NVu0bIhvW0GQR1XS
CPC-N NHXr[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKzU|JKSzVyPUSyMlk6PzFizszN M{\jTXNCVkeHUh?=
ES4 M3TyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LCbWlEPTB;NESuOFE2OyEQvF2= M4j6NnNCVkeHUh?=
Daudi NFrmbJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33QcGlEPTB;NEWuNFgzPyEQvF2= NEe0TlFUSU6JRWK=
HT-144 NXyyOYk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXDTWM2OD12Nj63NlYh|ryP MYPTRW5ITVJ?
SW872 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fIU2lEPTB;NEiuNVk{OyEQvF2= MortV2FPT0WU
D-283MED NXrMcotHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnqTWM2OD12OD6zOVQzKM7:TR?= MYnTRW5ITVJ?
NCI-H2126 NIDod45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;4bGNqUUN3ME20PE45PDd4IN88US=> NGPtdlZUSU6JRWK=
CESS M3rrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTC[I55UUN3ME20PU42ODh6IN88US=> NFXucm1USU6JRWK=
A101D NXv2OlFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXjTWM2OD12OT65O|M3KM7:TR?= M1XUcnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]


Kinase Assay:


+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:


+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.

    (Only for Reference)
Animal Research:


+ Expand
  • Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+dd H2O
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34


CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03737994 Not yet recruiting ALK Gene Rearrangement|ALK Positive|Non-Squamous Non-Small Cell Lung Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 National Cancer Institute (NCI) January 13 2019 Phase 2
NCT03672643 Not yet recruiting ALK-positive NSCLC Pfizer December 28 2018 Phase 4
NCT03707847 Recruiting ALK-Positive Anaplastic Large Cell Lymphoma Mingzhi Zhang|Zhengzhou University October 1 2018 Phase 4
NCT03646994 Recruiting Effectiveness and Safety for Real World Study on Crizotinib Used for ROS1 Arranged Non-squamous Non-small Cell Lung Cancer Hunan Province Tumor Hospital August 1 2018 --
NCT03647111 Recruiting Non-small Cell Lung Cancer Hunan Province Tumor Hospital August 1 2018 --
NCT03620643 Not yet recruiting Lobular Breast Carcinoma|Gastric Cancer Royal Marsden NHS Foundation Trust|Pfizer|Breast Cancer Now August 13 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • Answer:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products4

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID